RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
05 avr. 2023 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Lumiii Partners with University College London's EdTech Labs to Fundamentally Reshape Education Through Its Learn-to-Earn Gaming and Anime Series
07 juin 2022 07h00 HE
|
Lumiii
TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Secret Pirates Entertainment Inc., creators of The Secret Order of Lumiiis franchise, announces Lumiii has partnered with University College London's (UCL)...
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
22 févr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
03 sept. 2019 02h00 HE
|
Autolus Therapeutics plc
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...
Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
29 mars 2019 16h03 HE
|
Autolus Therapeutics plc
LONDON, March 29, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
04 mars 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Xtera and UCL demonstrate a record 74.38 Tbit/s per fiber transmission over transoceanic distances
28 févr. 2019 08h00 HE
|
Xtera
ALLEN, Texas and LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Xtera®, a provider of innovative subsea fiber optic technology, today demonstrates the benefits of its advanced and novel approach to...